Published in Nature on July 20, 2014
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell (2017) 1.38
Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood (2014) 1.05
LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Sci Rep (2015) 0.92
Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev (2015) 0.83
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia (2016) 0.82
Origin of cells and network information. World J Stem Cells (2015) 0.78
Notch signaling in prostate cancer: refining a therapeutic opportunity. Histol Histopathol (2015) 0.77
Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms. Oncotarget (2015) 0.76
Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Res (2015) 0.76
Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest (2016) 0.76
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica (2016) 0.75
High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia. Blood (2016) 0.75
Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders. Curr Opin Hematol (2016) 0.75
NOTCH1 downregulation contributes to PI3K inhibitor resistance in T-ALL. Cancer Discov (2014) 0.75
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. J Exp Clin Cancer Res (2016) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
BLAT--the BLAST-like alignment tool. Genome Res (2002) 126.78
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Versatile retroviral vectors for potential use in gene therapy. Gene Ther (1994) 5.33
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem (1997) 2.93
Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood (2004) 2.90
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol (2010) 2.58
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity (2010) 2.29
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell (2014) 1.79
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol (2006) 1.71
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55
Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol (2012) 1.52
Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res (2007) 1.44
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell (2013) 1.35
Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med (2011) 1.27
Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol (2013) 1.26
NOTCH and PI3K-AKT pathways intertwined. Cancer Cell (2007) 1.26
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia (2009) 1.23
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood (2013) 0.95
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol (2013) 0.94
Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem (2013) 0.91
Genomic landscape of paediatric adrenocortical tumours. Nat Commun (2015) 0.95